| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/07/2011 | EP2363405A1 Anti-infarction molecules |
| 09/07/2011 | EP2363404A2 PSMA antibodies |
| 09/07/2011 | EP2363397A1 Novel useful therapeutic agent for lower urinary tract symptom |
| 09/07/2011 | EP2363394A1 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorders |
| 09/07/2011 | EP2363147A1 Composition for local anesthesia |
| 09/07/2011 | EP2363140A1 Antisecretory protein for use in the treatment of compartiment syndrome |
| 09/07/2011 | EP2363138A1 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring periodontal diseases |
| 09/07/2011 | EP2363128A2 Indole modulators of ATP-binding cassette transporters |
| 09/07/2011 | EP2363125A1 Preparation for improving the sensitivity action of receptors |
| 09/07/2011 | EP2065388B1 Pyrazolopyrimidine derivative |
| 09/07/2011 | EP1239862B3 Pharmaceutical preparation containing cytostatic agents and electron acceptors for treating tumor diseases |
| 09/07/2011 | CN1582150B Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
| 09/07/2011 | CN102174520A Interference nucleic acid molecule and application thereof |
| 09/07/2011 | CN102174352A Chinese medicinal health-preserving health-protecting aged yellow wine |
| 09/07/2011 | CN102174097A Actinoporin and application thereof |
| 09/07/2011 | CN102174046A Tetomilast polymorphs |
| 09/07/2011 | CN102174044A Tetomilast polymorphs |
| 09/07/2011 | CN102174024A 2,4-pyrimidinediamine compounds and their uses |
| 09/07/2011 | CN102172403A Method for treating interleukin-6 related diseases |
| 09/07/2011 | CN102172357A Core 2 glcnac-t inhibitors |
| 09/07/2011 | CN102172351A Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
| 09/07/2011 | CN101695486B Use of chlorogenic acid in preparing medicament for treating marrow fibrillation |
| 09/07/2011 | CN101693014B Process for preparing coenzyme A medicament freeze drying preparation |
| 09/07/2011 | CN101597337B Conjugate of hydroxyalkyl starch and an active agent |
| 09/07/2011 | CN101597294B 3-aminoalkaneacylamino-rutaecarpine and 3-aminoalkaneacylamino-7,8-dehydrorutaecarpine derivative |
| 09/07/2011 | CN101407546B Human anti-human tumor necrosis factor-alpha single chain antibody |
| 09/07/2011 | CN101235004B Omega-amidosulphonic acid substituted hypocrellin derivatives, preparation method and application thereof |
| 09/06/2011 | US8013131 Synthetic membrane anchors |
| 09/06/2011 | US8013124 for stimulating the immune system, and proliferation and/or development of hematopoietic cells; production of proinflammatory cytokines |
| 09/06/2011 | US8012997 Isoindole-imide compounds, compositions, and uses thereof |
| 09/06/2011 | US8012996 Methods and composition for inhibition of angiogenesis |
| 09/06/2011 | US8012995 Pharmaceutically active sulfonamide derivatives |
| 09/06/2011 | US8012959 Diaminopyrimidinecarboxamide derivative |
| 09/06/2011 | US8012934 Small peptides and methods for treatment of inflammation |
| 09/06/2011 | US8012748 Peripheral nervous system specific sodium channel nucleic acids |
| 09/06/2011 | US8012711 Methods of screening for compounds that reduce microbial resistance to fluoroquinolones |
| 09/06/2011 | US8012503 Administering propranolol or a derivative across a mucosal membrane in combination with a buffering agent (phosphate buffer) to provide a pH of 7.6 at the membrane; sublingual; cardiovascular disorders |
| 09/06/2011 | US8012494 at least one non-ionic or zwitterionic surfactant and dispersant; improves the efficacy and/or potency of the lipase inhibitor; inter-subject variability in efficacy and/or potency is reduced, as well as the frequency and intensity of side effects |
| 09/06/2011 | US8012454 Embolization |
| 09/06/2011 | CA2656181C Compressed preparation of compositions comprising olmesartan medoxomil |
| 09/06/2011 | CA2498976C Medicinal formulation in particular for treating herniated invertebral discs |
| 09/06/2011 | CA2493785C Pyrimidyl sulphone amide derivatives as chemokine receptor modulators |
| 09/06/2011 | CA2488642C Aryl carbonyl derivatives as glucokinase activators |
| 09/06/2011 | CA2469275C 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors |
| 09/06/2011 | CA2466965C Sulphonamide derivatives, their preparation and use as medicaments |
| 09/06/2011 | CA2452260C Novel variants and exons of the glyt1 transporter |
| 09/06/2011 | CA2449419C Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
| 09/06/2011 | CA2446074C Carbonic anhydrase activators for enhancing learning and memory |
| 09/06/2011 | CA2439410C Analogs of thalidomide as potential angiogenesis inhibitors |
| 09/06/2011 | CA2415228C Treatment of bone diseases |
| 09/06/2011 | CA2411882C Solid valsartan pharmaceutical compositions |
| 09/06/2011 | CA2373360C Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| 09/06/2011 | CA2336361C Cavity induced allosteric modification of intermolecular interactions and methods of identifying compounds that effect the same |
| 09/01/2011 | WO2011106635A1 Treatment of sepsis using complement inhibitors |
| 09/01/2011 | WO2011106378A2 Oral b12 therapy |
| 09/01/2011 | WO2011105628A1 Pyrazolopyrimidine compounds and their use as pde10 inhibitors |
| 09/01/2011 | WO2011105590A1 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor |
| 09/01/2011 | WO2011105572A1 Novel heteroaryl derivative |
| 09/01/2011 | WO2011105568A1 Dried plant tissue and plant tissue extract for ameliorating central nervous system degenerative diseases accompanied by learning/memory disorders, movement disorders and the like, and pharmaceutical agent and food or beverage each comprising the dried plant tissue and the plant tissue extract |
| 09/01/2011 | WO2011105527A1 Nerve growth promoter |
| 09/01/2011 | WO2011105465A1 MAILLARD REACTION INHIBITOR, α-DICARBONYL COMPOUND DECOMPOSING AGENT, AND METHOD FOR INHIBITING THE MAILLARD REACTION |
| 09/01/2011 | WO2011105435A1 Therapeutic agent for eating disorders |
| 09/01/2011 | WO2011105424A1 Dendritic cell immunoreceptor stimulant |
| 09/01/2011 | WO2011105383A1 Agent for controlling production of primary bile acid and secondary bile acid |
| 09/01/2011 | WO2011105099A1 Compound containing a novel 4-alkoxypyridine formation and medicine containing same |
| 09/01/2011 | WO2010030366A3 Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method |
| 09/01/2011 | WO2008153813A8 Bone augmentation utilizing muscle-derived progenitor compositions, and treatments thereof |
| 09/01/2011 | US20110213470 Methods for using a three-dimensional stromal tissue to promote angiogenesis |
| 09/01/2011 | US20110213134 Synthetic membrane anchors |
| 09/01/2011 | US20110213011 Modulation of smad3 expression |
| 09/01/2011 | US20110213002 Macrocyclic diterpenes for treating conditions associated with protein kinase c |
| 09/01/2011 | US20110212983 Platelet adp receptor inhibitors |
| 09/01/2011 | US20110212981 Method of Determining a Chemotherapeutic Regimen Based on ERCC1 and TS Expression |
| 09/01/2011 | US20110212936 High-valent palladium fluoride complexes and uses thereof |
| 09/01/2011 | US20110212894 Decellularization method for scaffoldless tissue engineered articular cartilage or native cartilage tissue |
| 09/01/2011 | US20110212884 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
| 09/01/2011 | US20110212449 Distinguishing pca3 messenger rna species in benign and malignant prostate tissues |
| 09/01/2011 | US20110212195 Dispensing formulation |
| 09/01/2011 | US20110212194 Composition for Inhibiting Melanogenesis and Use Thereof |
| 09/01/2011 | US20110212160 Configurable microscopic medical payload delivery device to deliver nuclear signaling proteins to specific cells to manage diabetes mellitus and genetic deficiency disorders |
| 09/01/2011 | US20110212158 Immunocompatible chorionic membrane products |
| 09/01/2011 | US20110212022 Antitumor antibodies, proteins, and uses thereof |
| 09/01/2011 | CA2791166A1 Pyrazolopyrimidine compounds and their use as pde10 inhibitors |
| 09/01/2011 | CA2790996A1 Therapeutic agent for eating disorders |
| 09/01/2011 | CA2790708A1 Oral b12 therapy |
| 09/01/2011 | CA2789457A1 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor |
| 08/31/2011 | EP2362221A1 Antagonists of HMG1 for treating inflamatory conditions |
| 08/31/2011 | EP2361981A1 RNA sequence-specific mediators of RNA interference |
| 08/31/2011 | EP2361978A1 Polypeptides capable of eliciting an immune reaction against cancer |
| 08/31/2011 | EP2361923A2 Oligoribonucleotides and ribonucleases for cleaving RNA |
| 08/31/2011 | EP2361920A2 Preparation and use of carbohydrate-based ring structures with antimicrobial and cytostatic activity |
| 08/31/2011 | EP2361918A1 Novel prostaglandin e1 derivative, and nanoparticle having same encapsulated therein |
| 08/31/2011 | EP2361910A1 Compound having tafia inhibitory activity |
| 08/31/2011 | EP2361903A1 Benzenoid ansamycin derivative |
| 08/31/2011 | EP2361631A1 Treatment of alpha-galactosidase a deficiency |
| 08/31/2011 | EP2361622A1 Use of lipoxin analogs to promote cell defense against gram-negative infections |
| 08/31/2011 | EP2361613A1 Stabilized compositions of proteins having a free thiol moiety |
| 08/31/2011 | EP2031057B1 SENSE OLIGONUCLEOTIDE CAPABLE OF CONTROLLING THE EXPRESSION OF iNOS AND COMPOSITION COMPRISING THE SAME |
| 08/31/2011 | EP1521754B1 Viral inhibitors |
| 08/31/2011 | EP1506000B9 Heterocyclicsulfonamide hepatitis c virus inhibitors |